Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma
Summary
This summary is machine-generated.Rofecoxib does not cause cross-reactions in patients with aspirin-sensitive respiratory disease. This finding supports cyclooxygenase-1 inhibition as the primary cause of aspirin-induced respiratory reactions.
Area Of Science
- Pharmacology
- Immunology
- Respiratory Medicine
Background
- Aspirin-sensitive respiratory disease (ASRD) involves cross-reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) enzymes.
- The development of selective COX-2 inhibitors, like rofecoxib, raised questions about potential cross-reactivity in ASRD patients.
Purpose Of The Study
- To investigate whether rofecoxib triggers cross-reactions in patients with asthma sensitive to aspirin.
- To determine if selective COX-2 inhibition poses a risk for patients with ASRD.
Main Methods
- A double-blinded, placebo-controlled oral challenge study was conducted with 60 asthma patients.
- Patients received escalating doses of rofecoxib, followed by aspirin challenges to confirm sensitivity.
Main Results
- No patients exhibited symptoms, nasal changes, or reduced FEV(1) during rofecoxib challenges.
- All patients demonstrated typical reactions to aspirin, confirming their aspirin sensitivity.
- The probability of rofecoxib inducing cross-reactions was calculated to be between 0% and 0.05%.
Conclusions
- Rofecoxib does not appear to cause cross-reactivity in aspirin-sensitive patients with respiratory disease.
- The study strongly suggests that COX-1 inhibition is the key mechanism initiating aspirin-induced respiratory reactions.
- This research supports the use of selective COX-2 inhibitors in patients with ASRD, excluding immune-mediated reactions.
View abstract on PubMed